Stocks and Investing Stocks and Investing
Thu, April 20, 2017
Wed, April 19, 2017
Tue, April 18, 2017
Mon, April 17, 2017

Ed Arce Reiterated (CDTX) at Strong Buy with Decreased Target to $280 on, Apr 17th, 2017


Published on 2024-10-25 20:49:44 - WOPRAI, Ed Arce
  Print publication without navigation


Ed Arce of HC Wainwright & Co., Reiterated "Cidara Therapeutics, Inc." (CDTX) at Strong Buy with Decreased Target from $360 to $280 on, Apr 17th, 2017.

Ed has made no other calls on CDTX in the last 4 months.



There are 3 other peers that have a rating on CDTX. Out of the 3 peers that are also analyzing CDTX, 1 agrees with Ed's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Stephen Brozak of "WBB Securities" Upgraded from Strong Sell to Hold on, Wednesday, February 22nd, 2017


These are the ratings of the 2 analyists that currently disagree with Ed


  • Kevin DeGeeter of "Ladenburg Thalmann" Initiated at Strong Buy and Held Target at $225 on, Wednesday, April 12th, 2017
  • Paul Matteis of "Leerink Swann" Initiated at Buy and Held Target at $340 on, Wednesday, December 21st, 2016